Results 291 to 300 of about 61,821 (357)

Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer. [PDF]

Front Immunol
Frontiers Production Office.
europepmc   +1 more source

Figure 7 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia

Atham Ali, Alvin Phan, Vijaya Vaikari, Mincheol Park, Mateusz Pospiech, Ryan Chu, Yiting Meng, J. Andrew MacKay, Houda Alachkar   +8 more
openalex   +1 more source

In vivo CAR therapies: Turning the patient into their own CAR factory

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot, Carole‐Anne Brugère, Jaime Fuentealba, Roch Houot   +3 more
wiley   +1 more source

Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH. [PDF]

Biomark Res
Zhao B, Bu Q, Chen AL, Zhu HH.
europepmc   +1 more source

Data from IMiDs augment CD3-bispecific antibody induced CD8+ cell cytotoxicity and expansion by enhancing IL-2 production

Ji Li, Dionysos Slaga, Jennifer Johnston, Teemu T. Junttila   +3 more
openalex   +1 more source

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Relapse after chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T‐cells as standard second‐line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown because no real‐world data are currently ...
Pierre Sesques, Guillaume Manson, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Cristina Castilla‐Llorente, Gabriel Brisou, Pierre Bories, Catherine Thieblemont, Laurianne Drieu La Rochelle, Benoit Tessoulin, Axel André, Cedric Rossi, Jérôme Paillassa, Stephanie Guidez, Antoine Capes, Laura Herbreteau, Sylvain Choquet, Jacques‐Olivier Bay, Adrien Chauchet, Laure Lebras, Fabien Claves, Julie Abraham, Jean‐Valère Malfuson, Marie‐Thérèse Rubio, Justine Decroocq, Luc‐Matthieu Fornecker, Gandhi Damaj, Ludovic Fouillet, Magalie Joris, Michael Loschi, Olivier Hermine, Hadia Hafirassou, Emelie Van Zele, Vivien Dupont, Steven Le Gouill, Roch Houot, Vincent Camus   +37 more
wiley   +1 more source

The making of multispecific immunoglobulins - a clinical perspective. [PDF]

MAbs
Brinkmann U, Kontermann RE.
europepmc   +1 more source

Exploratory Biomarker Analysis of PD-1/CTLA-4 Bispecific Antibody Therapy Response in PD-L1-Negative Advanced Non-Small Cell Lung Cancer: Genomic and Transcriptomic Profiling from the Phase II LungCadX Study

Wang Li, Zhixuan Ren, Qi Wang, Li Liu, Shuai Lv, Minwei Bao, Tianqing Chu, Chuangzhou Rao, Jia-Ning Chen, Tianlin Sun, Changbin Zhu, Jialin Qu, Chunxia Su   +12 more
openalex   +1 more source

Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy. [PDF]

J Biol Eng
Lee J, Han G, Kyung M, Lee S, Kim TW, Jung ST.   +5 more
europepmc   +1 more source

Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations. [PDF]

Cancer Immunol Immunother
Fatahichegeni M, Ansarian MA, Xiao M, Gao W, Shi R.   +4 more
europepmc   +1 more source